原发性肝癌组织TACC3、p53蛋白表达变化及其与患者临床病理特征和预后的关系
|
摘要
目的探讨原发性肝癌组织转录相关酸性卷曲蛋白3(TACC3)、p53蛋白表达变化及其与患者临床病理特征和预后的关系。方法选择原发性肝癌组织和癌旁组织各112例份,采用Western blotting法检测TACC3、p53蛋白表达。分析原发性肝癌组织TACC3、p53蛋白表达与患者临床病理特征和预后的关系。结果原发性肝癌组织TACC3、p53蛋白相对表达量均明显高于癌旁组织(P均<0.05)。原发性肝癌组织TACC3、p53蛋白表达与肿瘤最大直径、临床分期、组织分化程度、淋巴结转移有关(P均<0.05),与性别、年龄、肿瘤数目无关(P均>0.05)。原发性肝癌组织TACC3表达与p53蛋白表达呈正相关关系(r=0.613,P<0.05)。以TACC3、p53蛋白表达的平均值为临界值,将患者分为TACC3或p53蛋白高表达者与低表达者。TACC3、p53蛋白高表达者3年生存率均明显低于其低表达者(χ~2分别为4.843、4.020,P均<0.05)。结论原发性肝癌组织TACC3、p53蛋白表达明显升高,其表达变化与肿瘤进展和患者预后不良有关。
Objective To investigate expression changes of transcription-related acidic crimp protein 3(TACC3) and p53 protein in patients with primary liver cancer and its relationships with the clinicopathological features and prognosis. Methods The cancer tissues and paracancerous tissues of 112 patients with primary liver cancer were selected. The expression of TACC3 and p53 protein in the tissues was detected by Western blotting. The relationships between expression of TACC3 and p53 protein and clinicopathological features and prognosis in primary liver cancer were analyzed. Results The expression of TACC3 and p53 protein in the cancer tissues was significantly higher than that in the adjacent tissues(P<0.05). The expression of TACC3 and p53 protein in the primary liver cancer was related to the maximum diameter, clinical stage, degree of tissue differentiation and lymph node metastasis(all P<0.05), but was not related to sex, age, or number of tumors(all P>0.05). There was a significant positive correlation between TACC3 and p53 expression(r=0.613, P<0.05). Taking the average expression of TACC3 and p53 protein as the critical value, we divided the patients into the TACC3 and p53 high expression group and TACC3 and p53 low expression groups. The 3-year survival rate of the high expression group was lower than that of the low expression group(χ~2=4.843 and 4.020, both P<0.05). Conclusion The expression of TACC3 and p53 protein in the primary liver cancer increases, and its expression changes are related to the progression of tumors and the prognosis of patients.
Objective To investigate expression changes of transcription-related acidic crimp protein 3(TACC3) and p53 protein in patients with primary liver cancer and its relationships with the clinicopathological features and prognosis. Methods The cancer tissues and paracancerous tissues of 112 patients with primary liver cancer were selected. The expression of TACC3 and p53 protein in the tissues was detected by Western blotting. The relationships between expression of TACC3 and p53 protein and clinicopathological features and prognosis in primary liver cancer were analyzed. Results The expression of TACC3 and p53 protein in the cancer tissues was significantly higher than that in the adjacent tissues(P<0.05). The expression of TACC3 and p53 protein in the primary liver cancer was related to the maximum diameter, clinical stage, degree of tissue differentiation and lymph node metastasis(all P<0.05), but was not related to sex, age, or number of tumors(all P>0.05). There was a significant positive correlation between TACC3 and p53 expression(r=0.613, P<0.05). Taking the average expression of TACC3 and p53 protein as the critical value, we divided the patients into the TACC3 and p53 high expression group and TACC3 and p53 low expression groups. The 3-year survival rate of the high expression group was lower than that of the low expression group(χ~2=4.843 and 4.020, both P<0.05). Conclusion The expression of TACC3 and p53 protein in the primary liver cancer increases, and its expression changes are related to the progression of tumors and the prognosis of patients.
引文
[1] 朱笑生,刘文超.原发性肝癌全球流行情况和危险因素的新进展[J].现代肿瘤医学,2018,26(14):2297-2301.
[2] Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China[J]. Hepatology, 2014,60(6):2099-2108.
[3] 樊嘉,周俭,杨欣荣.精准医学时代的肝癌外科治疗[J].中华消化外科杂志,2017,16(1):22-27.
[4] Ding ZM, Huang CJ, Jiao XF, et al. The role of TACC3 in mitotic spindle organization[J]. Cytoskeleton (Hoboken), 2017,74(10):369-378.
[5] Zhou DS, Wang HB, Zhou ZG, et al. TACC3 promotes stemness and is a potential therapeutic target in hepatocellular carcinoma[J]. Oncotarget, 2015,6(27):24163-24177.
[6] 令吉明,王建,徐晓琳,等.p53蛋白磷酸化及其功能[J].生命科学,2018,30(3):233-240.
[7] 中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肝胆病杂志,2011,20(11):929-946.
[8] Ettinger DS, Arnoletti JP, Gockerman JP, et al. Occult primary cancer clinical practice guidelines[J]. J Natl Compr Canc Netw, 2005,3(2):214-233.
[9] 李小江,牟睿宇,张洪,等.从气论治肝恶性肿瘤的经验举隅[J].国际中医中药杂志,2018,40(5):465-466.
[10] Du Y, Liu L, Wang C, et al. TACC3 promotes colorectal cancer tumourigenesis and correlates with poor prognosis[J]. Oncotarget, 2016,7(27):41885-41897.
[11] Li Q, Ye L, Guo W, et al. Overexpression of TACC3 is correlated with tumor aggressiveness and poor prognosis in prostate cancer[J]. Biochem Biophys Res Commun, 2017,486(4):872-878.
[12] Murata S, Campo L, Breuer EK. TACC3 in personalized medicine[J]. Oncoscience, 2015,2(10):847-848.
[13] 贺伟,母齐鸣,王刚,等.TACC3和p53蛋白在原发性肝癌组织中的表达及其临床意义[J].实用肿瘤学杂志,2018,32(25):420-425.
[14] Ha GH, Park JS, Breuer EK. TACC3 promotes epithelial-mesenchymal transition (EMT) through the activation of PI3K/Akt and ERK signaling pathways[J]. Cancer Lett, 2013,332(1):63-73.
[15] 王佳玉,杨卫平,林大伟,等.奥沙利铂对不同p53状态肝癌细胞中DNA损伤修复基因GADD45β的诱导差异及调控机制[J].中华肝胆外科杂志,2012,18(2):130-134.
[16] Ansari D, Del Pino Bellido C, Bauden M, et al. Centrosomal abnormalities in pancreatic cancer: molecular mechanisms and clinical implications[J]. Anticancer Res, 2018,38(3):1241-1245.
[17] 郭晓东,熊璐,曹晨,等.抑癌基因p53在肝癌组织中的异常表达及临床意义[J].现代生物医学进展,2012,12(1):66-68.
[18] Frattini V, Pagnotta SM, Tala F, et al. A metabolic function of FGFR3-TACC3 gene fusions in cancer[J]. Nature, 2018,553(7687):222-227.
[19] 贺伟,母齐鸣,王刚,等.TACC3和p53蛋白在原发性肝癌组织中的表达及其临床意义[J].实用肿瘤学杂志,2018,32(25):420-425.
[2] Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China[J]. Hepatology, 2014,60(6):2099-2108.
[3] 樊嘉,周俭,杨欣荣.精准医学时代的肝癌外科治疗[J].中华消化外科杂志,2017,16(1):22-27.
[4] Ding ZM, Huang CJ, Jiao XF, et al. The role of TACC3 in mitotic spindle organization[J]. Cytoskeleton (Hoboken), 2017,74(10):369-378.
[5] Zhou DS, Wang HB, Zhou ZG, et al. TACC3 promotes stemness and is a potential therapeutic target in hepatocellular carcinoma[J]. Oncotarget, 2015,6(27):24163-24177.
[6] 令吉明,王建,徐晓琳,等.p53蛋白磷酸化及其功能[J].生命科学,2018,30(3):233-240.
[7] 中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肝胆病杂志,2011,20(11):929-946.
[8] Ettinger DS, Arnoletti JP, Gockerman JP, et al. Occult primary cancer clinical practice guidelines[J]. J Natl Compr Canc Netw, 2005,3(2):214-233.
[9] 李小江,牟睿宇,张洪,等.从气论治肝恶性肿瘤的经验举隅[J].国际中医中药杂志,2018,40(5):465-466.
[10] Du Y, Liu L, Wang C, et al. TACC3 promotes colorectal cancer tumourigenesis and correlates with poor prognosis[J]. Oncotarget, 2016,7(27):41885-41897.
[11] Li Q, Ye L, Guo W, et al. Overexpression of TACC3 is correlated with tumor aggressiveness and poor prognosis in prostate cancer[J]. Biochem Biophys Res Commun, 2017,486(4):872-878.
[12] Murata S, Campo L, Breuer EK. TACC3 in personalized medicine[J]. Oncoscience, 2015,2(10):847-848.
[13] 贺伟,母齐鸣,王刚,等.TACC3和p53蛋白在原发性肝癌组织中的表达及其临床意义[J].实用肿瘤学杂志,2018,32(25):420-425.
[14] Ha GH, Park JS, Breuer EK. TACC3 promotes epithelial-mesenchymal transition (EMT) through the activation of PI3K/Akt and ERK signaling pathways[J]. Cancer Lett, 2013,332(1):63-73.
[15] 王佳玉,杨卫平,林大伟,等.奥沙利铂对不同p53状态肝癌细胞中DNA损伤修复基因GADD45β的诱导差异及调控机制[J].中华肝胆外科杂志,2012,18(2):130-134.
[16] Ansari D, Del Pino Bellido C, Bauden M, et al. Centrosomal abnormalities in pancreatic cancer: molecular mechanisms and clinical implications[J]. Anticancer Res, 2018,38(3):1241-1245.
[17] 郭晓东,熊璐,曹晨,等.抑癌基因p53在肝癌组织中的异常表达及临床意义[J].现代生物医学进展,2012,12(1):66-68.
[18] Frattini V, Pagnotta SM, Tala F, et al. A metabolic function of FGFR3-TACC3 gene fusions in cancer[J]. Nature, 2018,553(7687):222-227.
[19] 贺伟,母齐鸣,王刚,等.TACC3和p53蛋白在原发性肝癌组织中的表达及其临床意义[J].实用肿瘤学杂志,2018,32(25):420-425.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |